Predicted Trait | |
Reported Trait | Squamous cell carcinoma |
Mapped Trait(s) | squamous cell carcinoma (EFO_0000707) |
Additional Trait Information | PheCode 172.22 |
Score Construction | |
PGS Name | PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_P_5e-08_MGI_20200608 |
Development Method | |
Name | GWAS Hits |
Parameters | LD Clumping (MAF >= 1%, r^2 <= 0.1) & P<=5e-08 |
Variants | |
Original Genome Build | GRCh37 |
Number of Variants | 13 |
Effect Weight Type | NR |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000118 |
Citation (link to publication) | Fritsche LG et al. Am J Hum Genet (2020) |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
---|---|---|---|
GWAS Catalog: GCST003327 Europe PMC: 26829030 |
61,457 individuals | European | NR |
GWAS Catalog: GCST003655 Europe PMC: 27424798 |
287,137 individuals | European | NR |
GWAS Catalog: GCST003422 Europe PMC: 26908436 |
13,550 individuals | European | NR |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) | Phenotype Definitions & Methods | Age of Study Participants | Participant Follow-up Time | Additional Ancestry Description | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
Europe PMC: 32991828 |
[
|
European | MGI | PheCode:172.22; ICD9CM:173.02, 173.12, 173.22, 173.32, 173.42, 173.52, 173.62, 173.72, 173.82, 173.92; ICD10CM:C44.02, C44.121, C44.122, C44.129, C44.221, C44.222, C44.229, C44.320, C44.321, C44.329, C44.42, C44.520, C44.521, C44.529, C44.621, C44.622, C44.629, C44.721, C44.722, C44.729, C44.82, C44.92 | — | — | — | — |
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM001146 | PSS000545| European Ancestry| 8,473 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.491 [1.395, 1.593] β: 0.4 (0.0338) |
AUROC: 0.599 [0.579, 0.618] | Nagelkerke's Pseudo-R²: 0.0304 Brier score: 0.0974 Odds Ratio (OR, top 1% vs. Rest): 3.51 [2.29, 5.39] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_P_5e-08_MGI_20200608 |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS000545 | PheCode:172.22; ICD9CM:173.02, 173.12, 173.22, 173.32, 173.42, 173.52, 173.62, 173.72, 173.82, 173.92; ICD10CM:C44.02, C44.121, C44.122, C44.129, C44.221, C44.222, C44.229, C44.320, C44.321, C44.329, C44.42, C44.520, C44.521, C44.529, C44.621, C44.622, C44.629, C44.721, C44.722, C44.729, C44.82, C44.92 | — | [
|
— | European | — | MGI | — |